retatrutide type 2 diabetes trial results 2024 Lilly's triple agonist achieves 16.8% weight loss in phase 3 Retatrutide, a GIP, GLP-1 and
Description
00:06:33 Vickie Danaher So oral phentermine alone leads to about 8 pounds more weight loss than placebo
Ozempic is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes, not weight management
[1] Its mechanism promotes insulin secretion, slows gastric emptying, and reduces appetite, leading to notable improvements in glycaemic control and body weight reduction
doi: 10.1345/aph.1Q024
Ushio, A., et al
